Tenderwize
Retour à la recherche

Conclusion of non-exclusive drug discount agreement according to §130a(8) SGB V via Open-House model for the active substance Trientin (ATC: A16AX12)

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Sep 30, 2026 · 33 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Trientin (ATC-Code nach WHO: A16AX12)

40/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

40 / 100

Complexité

30 / 100

Facteurs de risque

No minimum volume guaranteed; actual prescriptions depend on doctors and pharmacies. Revenue may be negligible.

AOK PLUS may terminate the Open-House procedure if exclusive agreements are concluded, typically 8-12 months after publ...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Sep 2026
  • Non-exclusive drug discount agreements for the active substance Trientin (ATC: A16AX12)
  • Open-House model allowing any eligible pharmaceutical entrepreneur to participate
Afficher le résumé complet

This tender is a non-exclusive drug discount agreement (Open-House model) for the active substance Trientin (ATC: A16AX12) organized by AOK PLUS. It is not a traditional public procurement but is published for transparency. Any eligible pharmaceutical entrepreneur can participate at any time until 30 September 2026, subject to rolling submission deadlines. No minimum purchase volumes are guaranteed, and the agreement may be terminated early if exclusive agreements are concluded.

Risques

No minimum volume guaranteed; actual prescriptions depend on doctors and pharmacies. Revenue may be negligible.

AOK PLUS may terminate the Open-House procedure if exclusive agreements are concluded, typically 8-12 months after publ...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical entrepreneur as defined in §4(18) AMG

Eligibility

  • Must submit self-declaration on absence of exclusion grounds ($$§123,124 GWB)

Administrative

  • Must submit declaration on compliance with EU Russia sanctions (Regulation 833/2014)

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No specific award criteria disclosed; participation is based on acceptance of the framework terms.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Conclusion of non-exclusive drug discount agreement according to §130a(8) SGB V via Open-House model for the active substance Trientin (ATC: A16AX12)

Non-exclusive framework agreement for drug discounts on Trientin. Participation open to all eligible pharmaceutical companies. No minimum volumes. Agreement ends 30 September 2026.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Sep 2025 - Sep 2026

Catégorie

Pharmaceutical products

Critères d'attribution

No specific award criteria disclosed; participation is based on acceptance of the framework terms.

Date limite

Deadline Sep 30, 2026

Détails de la procédure

Date de publication
31 Jul 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
506508-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30